[go: up one dir, main page]

DK1575590T3 - Carbostyrilderivater og serotoningenoptagelsesinhibitorer til behandling af sindsstemningslidelser - Google Patents

Carbostyrilderivater og serotoningenoptagelsesinhibitorer til behandling af sindsstemningslidelser

Info

Publication number
DK1575590T3
DK1575590T3 DK03786308T DK03786308T DK1575590T3 DK 1575590 T3 DK1575590 T3 DK 1575590T3 DK 03786308 T DK03786308 T DK 03786308T DK 03786308 T DK03786308 T DK 03786308T DK 1575590 T3 DK1575590 T3 DK 1575590T3
Authority
DK
Denmark
Prior art keywords
serotonin reuptake
reuptake inhibitors
mood disorders
carbostyril derivatives
treat mood
Prior art date
Application number
DK03786308T
Other languages
Danish (da)
English (en)
Inventor
Tetsuro Kikuchi
Taro Iwamoto
Tsuyoshi Hirose
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32716306&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1575590(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Application granted granted Critical
Publication of DK1575590T3 publication Critical patent/DK1575590T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK03786308T 2002-12-27 2003-12-25 Carbostyrilderivater og serotoningenoptagelsesinhibitorer til behandling af sindsstemningslidelser DK1575590T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002379003 2002-12-27
US47048103P 2003-05-14 2003-05-14
PCT/JP2003/016724 WO2004060374A1 (en) 2002-12-27 2003-12-25 Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders

Publications (1)

Publication Number Publication Date
DK1575590T3 true DK1575590T3 (da) 2008-02-11

Family

ID=32716306

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03786308T DK1575590T3 (da) 2002-12-27 2003-12-25 Carbostyrilderivater og serotoningenoptagelsesinhibitorer til behandling af sindsstemningslidelser

Country Status (26)

Country Link
US (5) US9387182B2 (ru)
EP (2) EP1723957A3 (ru)
JP (1) JP4284524B2 (ru)
KR (2) KR100858852B1 (ru)
CN (2) CN1726039B (ru)
AT (1) ATE376419T1 (ru)
AU (1) AU2003295235B2 (ru)
BR (1) BR0317771A (ru)
CA (1) CA2511619C (ru)
CY (1) CY1108060T1 (ru)
DE (1) DE60317098T2 (ru)
DK (1) DK1575590T3 (ru)
EC (1) ECSP055885A (ru)
ES (1) ES2295677T3 (ru)
IL (1) IL169358A (ru)
MX (1) MXPA05006857A (ru)
MY (1) MY152919A (ru)
NO (1) NO333291B1 (ru)
NZ (2) NZ556779A (ru)
PE (1) PE20040923A1 (ru)
PL (1) PL211975B1 (ru)
PT (1) PT1575590E (ru)
RU (2) RU2356554C2 (ru)
SI (1) SI1575590T1 (ru)
WO (1) WO2004060374A1 (ru)
ZA (1) ZA200503873B (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102166359A (zh) * 2003-05-23 2011-08-31 大塚制药株式会社 用于治疗情感障碍的喹诺酮衍生物和情绪稳定剂
EP1797039A1 (en) * 2004-09-13 2007-06-20 Matrix Laboratories Ltd Process for the preparation of polymorphs, solvates of aripiprazole using aripiprazole acid salts
WO2006050037A1 (en) * 2004-10-28 2006-05-11 Sk Corporation Adjunctive therapy for depression
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
GB2456183A (en) 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
JOP20120083B1 (ar) * 2011-04-05 2021-08-17 Otsuka Pharma Co Ltd توليفات تشتمل على بريكس ببرازول أو ملح منه وعقار ثاني للاستخدام في علاج اضطراب cns
JO3227B1 (ar) 2011-09-08 2018-03-08 Otsuka Pharma Co Ltd مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
WO2014002553A1 (ja) 2012-06-29 2014-01-03 丸石製薬株式会社 アリピプラゾールの経口医薬製剤
GB2542155B (en) 2015-09-09 2018-08-01 Gw Pharma Ltd Use of cannabidiol in the treatment of mental disorders
CN111455019A (zh) * 2018-05-03 2020-07-28 杭州端丽生物技术有限公司 化合物fty720在制备治疗行为和运动异常检测标记物中的应用
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
JP7211136B2 (ja) * 2019-02-14 2023-01-24 ニプロ株式会社 錠剤、および、その製造方法
CN114340607A (zh) 2019-05-13 2022-04-12 瓦西特拉有限公司 利用自噬激活预防或治疗退行性脑部疾病的药物组合物
EP3970711A4 (en) 2019-05-15 2023-07-05 VASTHERA Co. Ltd. COMPOSITION FOR PREVENTING OR TREATING CARDIO-CEREBRO-VASCULAR DISEASES COMPRISING AS ACTIVE PRINCIPLE AN AUTOPHAGY ACTIVATOR
US11080484B1 (en) * 2020-10-08 2021-08-03 Omniscient Neurotechnology Pty Limited Natural language processing of electronic records

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4310524A (en) 1980-04-11 1982-01-12 Richardson-Merrell, Inc. TCA Composition and method for rapid onset antidepressant therapy
JP2608788B2 (ja) 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
US5114976A (en) 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US5591884A (en) 1989-05-31 1997-01-07 Abbott Laboratories Dopamine agonists
US5500343A (en) 1990-02-07 1996-03-19 Board Of Regents, The University Of Texas System Allelic association of the human dopamine(D2) receptor gene in compulsive disorders
US5780051A (en) 1992-04-02 1998-07-14 Dynagen, Inc. Methods and articles of manufacture for nicotine cessation and monitoring nicotine use
US5663167A (en) 1992-12-09 1997-09-02 The United States Of America As Represented By The Department Of Health And Human Services Antipsychotic composition and method of treatment
IE930485A1 (en) 1993-06-28 1994-12-28 Hemisphere Ltd Antidepressant agents with a rapid onset of action
ZA948357B (en) 1994-06-16 1996-04-24 Lilly Co Eli Potentiation of drug response
HUP9903684A3 (en) 1995-12-22 2001-12-28 Lilly Co Eli Use of olanzapine for the preparation of pharmaceutical compositions treating depression
AU2587297A (en) 1996-03-25 1997-10-17 Eli Lilly And Company Method for treating pain
CZ296263B6 (cs) 1996-03-25 2006-02-15 Eli Lilly And Company Farmaceutická kompozice pro lécení bolesti a jejípouzití
US6159963A (en) 1996-03-29 2000-12-12 Eli Lilly And Company Method for treating substance abuse
IL121076A (en) 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
ZA977967B (en) 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
ZA982368B (en) 1997-03-27 1998-09-23 Akzo Nobel Nv New therapeutic combinations
AU9692898A (en) 1997-10-17 1999-05-10 Eli Lilly And Company Potentiation of pharmaceuticals
GB9801538D0 (en) 1998-01-23 1998-03-25 Merck Sharp & Dohme Pharmaceutical product
CA2328197C (en) 1998-04-14 2007-11-20 The General Hospital Corporation Methods for treating neuropsychiatric disorders
GB2336534A (en) 1998-04-24 1999-10-27 Alec James Coppen Anti-depressant - Folic Acid Combination
US6500827B2 (en) 1998-05-08 2002-12-31 Pharmacia & Upjohn Company Drug combinations
BR9909559A (pt) 1998-05-08 2000-12-19 Upjohn Co Novas combinações de drogas
AU3891299A (en) 1998-05-21 1999-12-06 Eli Lilly And Company Combination therapy for treatment of depression
US6960577B2 (en) 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
JP2002516282A (ja) 1998-05-22 2002-06-04 イーライ・リリー・アンド・カンパニー 難治性鬱病の処置のための組合せ治療
TR200003525T2 (tr) 1998-05-29 2001-04-20 Eli Lilly And Company Bipolar bozuklukların tedavisi için kombinasyon terapisi
US20030027817A1 (en) 1998-05-29 2003-02-06 Tollefson Gary Dennis Combination therapy for treatment of bipolar disorders
US6420349B1 (en) 1998-08-24 2002-07-16 Bristol-Myers Squibb Company Isoxazolinone antibacterial agents
DE69923081T2 (de) 1998-11-23 2005-12-08 Sepracor Inc., Marlborough Desmethylolanzapine enthaltende zusammensetzungen und verfahren
AU757870B2 (en) 1998-11-23 2003-03-06 Sepracor, Inc. Pharmaceutical compositions containing olanzapine-N-oxide
EP1133299A1 (en) 1998-11-23 2001-09-19 Sepracor Inc. 2-hydroxymethylolanzapine compositions and methods
WO2000054764A2 (en) 1999-03-18 2000-09-21 Children's Hospital Research Foundation A method of treating bulimia nervosa and related eating disorders by administration of atypical antipsychotic medications
JP2002541098A (ja) 1999-04-06 2002-12-03 セプラコア インコーポレーテッド ジプラシドン代謝産物を用いる神経弛緩薬性障害および関連障害を治療するための方法および組成物
US6281207B1 (en) 1999-09-15 2001-08-28 Reed Richter Treatment of movement disorders by administration of mirtazapine
US6599532B2 (en) 2000-01-13 2003-07-29 Osmotica Corp. Osmotic device containing alprazolam and an antipsychotic agent
US6572890B2 (en) 2000-01-13 2003-06-03 Osmotica Corp. Osmotic device containing venlafaxine and an anti-psychotic agent
US6322503B1 (en) 2000-02-17 2001-11-27 G. Roger Sparhawk, Jr. Method of diagnosing, tracking, and treating depression
DE10018834A1 (de) 2000-04-15 2001-10-25 Lohmann Therapie Syst Lts Transdermale oder transmucosale Darreichungsformen mit einer nicotinhaltigen Wirkstoffkombination zur Raucherentwöhnung
MXPA03006003A (es) * 2001-01-02 2005-09-08 Upjohn Co Nuevas combinaciones de farmacos.
AR032641A1 (es) * 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
US20020123490A1 (en) 2001-03-01 2002-09-05 Pfizer Inc. Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis
WO2002072145A1 (en) 2001-03-14 2002-09-19 Ono Pharmaceutical Co., Ltd. Remedies for depression containing ep1 antagonist as the active ingredient
CA2444053C (en) 2001-04-19 2008-06-17 Warner-Lambert Company Llc Fused bicyclic or tricyclic amino acids
US20030109546A1 (en) 2001-04-26 2003-06-12 Fenton Wayne S. Treatment of psychotic disorders comprising co-therapy with anticonvulsant derivatives and atypical antipsychotics
DE10129320A1 (de) 2001-06-19 2003-04-10 Norbert Mueller Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
US6582737B2 (en) 2001-09-25 2003-06-24 Peirce Management, Llc Pharmaceutical composition containing two active ingredients for smoking cessation
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
CA2475839A1 (en) 2002-02-08 2003-08-14 Abbott Laboratories Combination therapy for treatment of schizophrenia
EP1336406A1 (en) 2002-02-14 2003-08-20 Solvay Pharmaceuticals B.V. Partial dopamine-D2 receptor agonist plus serotonin and/or noradrenaline inhibitory activity
AU2003227521A1 (en) 2002-05-30 2003-12-19 Neurosearch A/S Combination of atypical antipsychotic and serotonin reuptake inhibitor for the treatment of chronic pain
CA2494109A1 (en) 2002-07-29 2004-02-05 Potomac, Pharma, Llc. Antipsychotic combination therapies and compositions of an alpha-2 adrenergic receptor antagonist and an atypical antipsychotic neuroleptic
MXPA05000294A (es) 2002-07-30 2005-08-19 Peter Migaly Terapia combinada para la depresion, prevencion de suicidios y varias condiciones medicas y psiquiatricas.
MXPA05004422A (es) 2002-10-25 2007-11-22 Collegium Pharmaceutical Inc Composiciones de milnacipran de liberacion pulsatil.
US20040132826A1 (en) 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
CN102166359A (zh) 2003-05-23 2011-08-31 大塚制药株式会社 用于治疗情感障碍的喹诺酮衍生物和情绪稳定剂
EP1667686A1 (en) 2003-09-09 2006-06-14 Pfizer Products Inc. Combination of serotonin reuptake inhibitors and norepinephrine reuptake inhibitors
WO2005051488A1 (en) 2003-11-26 2005-06-09 Pfizer Products Inc. Combination of dopamine agonists and monoamine reuptake inhibitors
EP1713486A4 (en) 2003-12-02 2009-04-29 Sheldon Leslie James COMBINED THERAPY FOR THE TREATMENT OF DEMENTIA, DEPRESSION AND APATHY

Also Published As

Publication number Publication date
NO20052359L (no) 2005-07-18
CY1108060T1 (el) 2014-02-12
US20200289501A1 (en) 2020-09-17
IL169358A (en) 2013-04-30
HK1101550A1 (en) 2007-10-18
JP4284524B2 (ja) 2009-06-24
PT1575590E (pt) 2007-12-06
EP1723957A2 (en) 2006-11-22
EP1575590B1 (en) 2007-10-24
KR100842694B1 (ko) 2008-07-01
MY152919A (en) 2014-12-15
KR100858852B1 (ko) 2008-09-17
DE60317098D1 (de) 2007-12-06
ZA200503873B (en) 2006-08-30
NZ540054A (en) 2007-09-28
WO2004060374A1 (en) 2004-07-22
KR20050085906A (ko) 2005-08-29
CA2511619C (en) 2011-07-12
US9387182B2 (en) 2016-07-12
CN1726039B (zh) 2010-08-18
IL169358A0 (en) 2007-07-04
EP1575590A1 (en) 2005-09-21
BR0317771A (pt) 2005-11-22
JP2004217650A (ja) 2004-08-05
AU2003295235A1 (en) 2004-07-29
SI1575590T1 (sl) 2008-04-30
ES2295677T3 (es) 2008-04-16
RU2356554C2 (ru) 2009-05-27
NO333291B1 (no) 2013-04-29
ECSP055885A (es) 2005-11-22
RU2005123808A (ru) 2006-02-20
PE20040923A1 (es) 2005-01-22
CN1726039A (zh) 2006-01-25
PL378214A1 (pl) 2006-03-20
HK1145291A1 (en) 2011-04-15
CA2511619A1 (en) 2004-07-22
PL211975B1 (pl) 2012-07-31
NO20052359D0 (no) 2005-05-12
US9694009B2 (en) 2017-07-04
RU2389490C2 (ru) 2010-05-20
US20160310489A1 (en) 2016-10-27
EP1723957A3 (en) 2013-01-23
NZ556779A (en) 2008-12-24
US20140221388A1 (en) 2014-08-07
ATE376419T1 (de) 2007-11-15
DE60317098T2 (de) 2008-08-07
KR20070093001A (ko) 2007-09-14
AU2003295235B2 (en) 2008-06-19
RU2008131331A (ru) 2010-02-10
CN1989968B (zh) 2011-05-11
US20190151308A1 (en) 2019-05-23
CN1989968A (zh) 2007-07-04
US20170258788A1 (en) 2017-09-14
HK1082411A1 (zh) 2006-06-09
MXPA05006857A (es) 2005-08-18

Similar Documents

Publication Publication Date Title
DK1575590T3 (da) Carbostyrilderivater og serotoningenoptagelsesinhibitorer til behandling af sindsstemningslidelser
DE60332433D1 (de) Azolylaminoazine als proteinkinasehemmer
DE60332604D1 (de) Azolylaminoazine als proteinkinasehemmer
CY1116754T1 (el) Παραγωγα νιτροκατεχολης ως αναστολεις της comt
NO20034056D0 (no) Proliferative sykdommer
DK1954274T3 (da) Substituerede quinoloner og fremgangsmåder til anvendelse
ATE478664T1 (de) Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren
CY1112238T1 (el) Αναστολεις μιτωτικης κινεσινης και μεθοδοι χρησης αυτων
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
PT1347971E (pt) Inibidores tiazolilicos de tirosina-cinases da familia tec
EA200900798A1 (ru) Производные индол-4-илпиримидинил-2-иламина и их применение в качестве ингибиторов циклинзависимой киназы
NO20052888L (no) Diamintriazoler anvendelige som inhibitorer av proteinkinaser
DE60314603D1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
NO20072567L (no) Triazoler nyttige som proteinkinase-inhibitorer
SV2009003212A (es) Inhibidores de metaloproteasa derivados de heterociclicos ref. prd2727svpct
NO20060392L (no) Kombinasjon av SRC kinase inhibitorer kemoterapeutiske midler for behandling av proliferative sykdommer
UY28098A1 (es) Derivados de anilinopirazol útiles en el tratamiento de la diabetes
ATE432281T1 (de) Pyrrolotriazin-kinasehemmer
ATE502935T1 (de) C-met-proteinkinasehemmer
DK1919466T3 (da) Formuleringer til behandling af lipoprotein-abnormiteter omfattende et statin og et methylnicotinamidderivat
NO20065762L (no) Prodroger av pyrrolypyrimidin-ERK-proteinkinaseinhibitorer.
GEP20104888B (en) Use of carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
DK1071463T3 (da) Fremgangsmåde og samensætninger ved anvendelse af terfenadinmetabolitter i kombination med leukotrieninhibitorer
FI20031191A7 (fi) Monoamiinin takaisinoton estäjä
ATE423772T1 (de) Morpholinderivate als inhibitoren der wiederaufnahme von norepinephrin